Overview

A Study of HS-20093 vs Active Surveillance in Limited-Stage Small Cell Lung Cancer

Status:
NOT_YET_RECRUITING
Trial end date:
2029-01-31
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy, safety and tolerability of HS-20093 compared with active surveillance as consolidation therapy after chemoradiotherapy in participants with limited-stage small cell lung cancer.
Phase:
PHASE3
Details
Lead Sponsor:
Hansoh BioMedical R&D Company